Search

Displaying results 1941 - 1950 of 4344 in total
  1. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.

  2. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression

  3. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

  4. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  5. Drug

    Alpha-1-proteinase inhibitor

    go.drugbank.com/drugs/DB00058
    ApprovedInvestigational

    Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.

  6. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

  7. Drug

    Riluzole

    go.drugbank.com/drugs/DB00740
    ApprovedInvestigational

    Riluzole is marketed as Rilutek by Sanofi.

    Products: GLENTEK 50MG, RILUTEK 50MG
  8. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  9. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics.

  10. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Fat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041 … It is a rich source of monounsaturated and saturated fatty acids [A33040] that mainly contains approximately 33% [DB04224], 25% [DB03796], and 33% [DB03193] [A20409] but does not contain caffeine or theobromine